Russell Investments Group Ltd. Has $8.09 Million Position in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Russell Investments Group Ltd. raised its position in Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 9.7% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 116,243 shares of the company’s stock after purchasing an additional 10,320 shares during the period. Russell Investments Group Ltd.’s holdings in Dr. Reddy’s Laboratories were worth $8,088,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of the business. GAMMA Investing LLC bought a new stake in shares of Dr. Reddy’s Laboratories in the fourth quarter valued at approximately $34,000. PDS Planning Inc increased its stake in Dr. Reddy’s Laboratories by 6.3% in the fourth quarter. PDS Planning Inc now owns 5,239 shares of the company’s stock valued at $365,000 after acquiring an additional 309 shares during the last quarter. CWM LLC lifted its position in shares of Dr. Reddy’s Laboratories by 37.9% during the 4th quarter. CWM LLC now owns 2,174 shares of the company’s stock worth $151,000 after buying an additional 598 shares during the last quarter. Signaturefd LLC lifted its holdings in shares of Dr. Reddy’s Laboratories by 5.1% in the fourth quarter. Signaturefd LLC now owns 21,272 shares of the company’s stock worth $1,480,000 after acquiring an additional 1,032 shares during the last quarter. Finally, Lindbrook Capital LLC lifted its stake in Dr. Reddy’s Laboratories by 19.1% in the 4th quarter. Lindbrook Capital LLC now owns 3,519 shares of the company’s stock valued at $245,000 after purchasing an additional 565 shares during the last quarter. Institutional investors and hedge funds own 14.02% of the company’s stock.

Dr. Reddy’s Laboratories Stock Down 4.6 %

Dr. Reddy’s Laboratories stock opened at $71.44 on Wednesday. Dr. Reddy’s Laboratories Limited has a 1-year low of $53.12 and a 1-year high of $77.72. The company has a current ratio of 2.55, a quick ratio of 1.90 and a debt-to-equity ratio of 0.02. The firm’s fifty day moving average price is $73.82 and its two-hundred day moving average price is $70.84. The firm has a market capitalization of $11.92 billion, a price-to-earnings ratio of 18.85, a price-to-earnings-growth ratio of 1.88 and a beta of 0.57.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on RDY. Barclays boosted their price objective on Dr. Reddy’s Laboratories from $75.00 to $80.00 and gave the stock an “overweight” rating in a research report on Monday, January 29th. Jefferies Financial Group downgraded Dr. Reddy’s Laboratories from a “buy” rating to an “underperform” rating in a research note on Thursday, January 11th. Finally, StockNews.com downgraded shares of Dr. Reddy’s Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 30th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $80.00.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.